Cyclopharm Limited (ASX: CYC)
Australia
· Delayed Price · Currency is AUD 2.120
-0.010 (-0.47%)
Jan 21, 2025, 4:10 PM AEST
Cyclopharm Income Statement
Financials in millions AUD. Fiscal year is January - December.
Millions AUD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Operating Revenue | 23.7 | 26.34 | 22.88 | 17.7 | 14.68 | 14.08 | Upgrade
|
| Other Revenue | 0.36 | 0.8 | 1.98 | 2.29 | 3 | 2.93 | Upgrade
|
| Revenue | 24.06 | 27.14 | 24.85 | 20 | 17.68 | 17.01 | Upgrade
|
| Revenue Growth (YoY) | -19.10% | 9.19% | 24.30% | 13.09% | 3.93% | 9.57% | Upgrade
|
| Cost of Revenue | 10.23 | 10.26 | 7.44 | 5.04 | 3.96 | 2.91 | Upgrade
|
| Gross Profit | 13.82 | 16.88 | 17.41 | 14.95 | 13.72 | 14.1 | Upgrade
|
| Selling, General & Admin | 25.73 | 21.14 | 18.69 | 16.68 | 14.35 | 11.87 | Upgrade
|
| Research & Development | 0.82 | 3.69 | 3.44 | 1.66 | 3.54 | 4.19 | Upgrade
|
| Other Operating Expenses | -0.02 | 0.34 | 0.35 | 0.52 | 0.4 | 0.68 | Upgrade
|
| Operating Expenses | 27.77 | 26.11 | 23.41 | 19.61 | 19.2 | 17.74 | Upgrade
|
| Operating Income | -13.94 | -9.22 | -6 | -4.66 | -5.48 | -3.64 | Upgrade
|
| Interest Expense | -0.22 | -0.22 | -0.27 | -0.09 | -0.21 | -0.28 | Upgrade
|
| Interest & Investment Income | 0.4 | 0.49 | 0.11 | 0 | 0 | 0.03 | Upgrade
|
| Currency Exchange Gain (Loss) | 0.19 | 0.19 | 0.12 | 0.26 | -0.65 | 0.15 | Upgrade
|
| Other Non Operating Income (Expenses) | -0.01 | - | - | - | - | - | Upgrade
|
| EBT Excluding Unusual Items | -13.58 | -8.77 | -6.03 | -4.49 | -6.34 | -3.74 | Upgrade
|
| Asset Writedown | 3.16 | 3.16 | - | - | - | - | Upgrade
|
| Legal Settlements | 1.28 | 1.28 | - | - | 0 | 0.34 | Upgrade
|
| Other Unusual Items | - | - | - | - | 0.49 | 0.98 | Upgrade
|
| Pretax Income | -9.01 | -4.19 | -6.03 | -4.35 | -5.84 | -2.42 | Upgrade
|
| Income Tax Expense | 0.31 | 0.51 | 0.58 | 0.69 | 0.2 | 0.49 | Upgrade
|
| Net Income | -9.32 | -4.7 | -6.61 | -5.04 | -6.04 | -2.91 | Upgrade
|
| Net Income to Common | -9.32 | -4.7 | -6.61 | -5.04 | -6.04 | -2.91 | Upgrade
|
| Shares Outstanding (Basic) | 95 | 93 | 92 | 90 | 77 | 68 | Upgrade
|
| Shares Outstanding (Diluted) | 95 | 93 | 92 | 90 | 77 | 68 | Upgrade
|
| Shares Change (YoY) | 2.93% | 0.53% | 2.77% | 17.10% | 12.43% | 0.22% | Upgrade
|
| EPS (Basic) | -0.10 | -0.05 | -0.07 | -0.06 | -0.08 | -0.04 | Upgrade
|
| EPS (Diluted) | -0.10 | -0.05 | -0.07 | -0.06 | -0.08 | -0.04 | Upgrade
|
| Free Cash Flow | -12.7 | -7.43 | -7.94 | -2.47 | -9.13 | -0.53 | Upgrade
|
| Free Cash Flow Per Share | -0.13 | -0.08 | -0.09 | -0.03 | -0.12 | -0.01 | Upgrade
|
| Dividend Per Share | - | 0.005 | 0.010 | 0.010 | 0.010 | 0.010 | Upgrade
|
| Dividend Growth | - | -50.00% | 0% | 0% | 0% | 0% | Upgrade
|
| Gross Margin | 57.47% | 62.21% | 70.06% | 74.78% | 77.58% | 82.90% | Upgrade
|
| Operating Margin | -57.95% | -33.99% | -24.13% | -23.31% | -31.01% | -21.39% | Upgrade
|
| Profit Margin | -38.72% | -17.32% | -26.60% | -25.21% | -34.18% | -17.12% | Upgrade
|
| Free Cash Flow Margin | -52.79% | -27.39% | -31.94% | -12.36% | -51.63% | -3.10% | Upgrade
|
| EBITDA | -12.98 | -8.56 | -5.36 | -4.19 | -4.86 | -3.19 | Upgrade
|
| EBITDA Margin | -53.95% | -31.55% | -21.55% | -20.96% | -27.50% | -18.76% | Upgrade
|
| D&A For EBITDA | 0.96 | 0.66 | 0.64 | 0.47 | 0.62 | 0.45 | Upgrade
|
| EBIT | -13.94 | -9.22 | -6 | -4.66 | -5.48 | -3.64 | Upgrade
|
| EBIT Margin | -57.95% | -33.99% | -24.13% | -23.31% | -31.01% | -21.39% | Upgrade
|
| Revenue as Reported | 29.04 | 32.21 | 24.96 | 20.14 | 17.69 | 17.04 | Upgrade
|
| Advertising Expenses | - | 0.98 | 0.54 | 0.3 | 0.21 | 0.24 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.